What you should know:
1. The partnership aims to develop at least five drug discovery programs. Evotec aims to deliver clinical candidates to Takeda, which can then take them through clinical development.
2. The program will target Takeda’s four key development areas: oncology, gastroenterology, neuroscience and rare disease.
3. Takeda paid Evotec a one-time, upfront fee. Evotec is eligible for several milestone-related payments totaling more than $170 million per program, and Evotec will be paid royalties on future sales.
More articles on surgery centers:
Florida ASC project wraps up within $6M budget — 5 details
Orthopedic ASC opens in North Carolina
6 cardiovascular ASCs opened, announced in 2019
